Mar 02, 2020
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
Mar 01, 2020
Gilad&Gilad enters Taiwan with AgmaVet®, a Veterinary Product for Nerve Health
Feb 26, 2020
FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Feb 25, 2020
Techron® Marine Fuel System Treatment Now Featured in All West Marine Stores Nationwide
Jan 29, 2020
Dr. David Mahjoubi of Ketamine Healing Clinic Named 2020 Top Doctor by Los Angeles Magazine
Jan 28, 2020
Global Hindered Amine Light Stabilizers Market Analysis, Trends, and Forecasts 2019-2027 - ResearchAndMarkets.com
Jan 27, 2020
Tuberous Sclerosis Alliance Lauds Lundbeck And FDA For Sabril Label Expansion For Patients 2 To 10 Years Old
Dec 23, 2019
New York City based IV Drips now offers Ketamine and NAD+ Infusions
Dec 18, 2019
The Ketamine Fund Donates 400 Free Treatments To Veterans
Dec 13, 2019
CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Dec 10, 2019
Neurologists Anticipate Overall Expansion of the Fumarate Class Following the US Launch of Biogen's Vumerity for Treatment in Multiple Sclerosis, According to Spherix Global Insights
Dec 06, 2019
Enteris BioPharma's Licensing Partner, Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA(TM) for the Treatment of Pruritus in Patients with Advanced Chronic Kidney Disease (CKD)
Nov 25, 2019
Ketamine Clinics Los Angeles Featured on Emmy® Award-Winning Talk Show The Doctors
Nov 13, 2019
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Nov 12, 2019
Breckenridge Announces Final Approval of ANDA for Erlotinib Hydrochloride Tablets (generic for Tarceva®)
Nov 07, 2019
Ketamine Holds Promise in Derailing Veteran Suicide
Oct 31, 2019
Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT
Oct 30, 2019
Information Update - Ranbaxy Pharmaceuticals Canada Inc. recalls prescription ranitidine products as a precaution; request to stop distribution remains in place while Health Canada continues to assess NDMA
Oct 15, 2019
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Oct 14, 2019
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15